Montefiore Health System | Strategic Alliance Partners

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, discussed his experience in establishing a neurology department committee on diversity, equity, and inclusion. [WATCH TIME: 5 minutes]

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, provided insight on the need to improve online resources that provide epilepsy surgery information to patients. [WATCH TIME: 4 minutes]

The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]

The director of the Montefiore Einstein Center for the Aging Brain detailed the efforts being made to support individuals in underrepresented communities and raise awareness for cognitive decline. [WATCH TIME: 4 minutes]

The director of the Montefiore Einstein Center for the Aging Brain provided insight on how the 5-Cog assessment tool is specifically tailored for people from a range of racial and ethnic background, education levels, and socioeconomic circumstances. [WATCH TIME: 4 minutes]

The director of the Montefiore Einstein Center for the Aging Brain provided perspective on a new study assessing the use of a novel tool aimed to confirm patients’ cognitive complaints and issues with mobility.

In a post-hoc analysis of the ADVANCE trial, atogepant 30 and 60 mg produced significant improvements in outcomes on Migraine-Specific Quality of Life Questionnaire and Activity Impairment in Migraine-Diary domains.

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

Data from a cohort of almost 5000 women seen at Montefiore Health System emergency departments suggest that primary headache, likely migraine, is underdiagnosed, and a high proportion of these women being of Black and Hispanic backgrounds.

The director of the Montefiore Headache Center spoke about the Migraine Clinical Outcome Assessment System project and the need for better patient-reported outcome measures in migraine clinical care.

Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.

In 2 pivotal trials, the agent showed statistically significant superiority over placebo at 2 hours on coprimary end points of pain freedom and freedom from the most bothersome symptom.

Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.

The resident physician at Montefiore Medical Center shared her experience with the novel and standardized quick examination tool and the data presented at AAN 2022. [WATCH TIME: 3 minutes]

In an assessment including 23 patients, the novel and standardized quick neurologic examination showed excellent interrater reliability and agreement, suggesting good validity.

The investigators concluded that the MIDAS questionnaire may be a useful tool in the development, testing, and prescription of cost-effective medications for those with migraine whose direct and indirect costs are high.

Perceived negative effects on health care included disruption of interventional treatments that required in-person contact, concerns about losing healthcare providers, reluctance to use urgent care, and difficulty in obtaining certain medications due to shortages.

Overall, more than 40% of the cohort were eligible for a migraine preventive medication, but only 16.8% reported currently using one.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center provided thoughts on the need to improve awareness of sleep disorders and identifying those who may be eligible for treatment, including pediatric patients. [WATCH TIME: 2 minutes]

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center provided knowledge on how the presence of other comorbid sleep disorders affects patients with insomnia. [WATCH TIME: 2 minutes]

Years of built-up trust in the community has enabled Montefiore’s Stern Stroke Center physicians to understand more about how stroke affects multicultural communities and to break down existing barriers to care.

Despite projections that aducanumab (Aduhelm; Biogen) would be widely adopted in clinical practice after its June 2021 approval, financial reports suggest a different story. Jessica Zwerling, MD, MS, and Lon Schnider, MD, MS, offered their perspectives on its clinical application thus far.

Individuals with chronic and episodic migraine saw improvements in patient-reported outcomes such as MSQoL, EQ-5D-5L, PGIC, WPAI, and the 9-Item Patient Health Questionnaire.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jessica Zwerling, MD, MS.

The director of Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease, associate professor of neurology, Albert Einstein College of Medicine, discussed recent developments in Alzheimer disease research, including FDA approval of aducanumab, as well as the importance of engaging community-based organizations to improve patient care.

The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease commented on social determinants of health in relation to telemedicine and community willingness to engage.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center discussed the adjustments clinicians and patients with sleep disorders made throughout the pandemic, including the increased use of telemedicine.